ArticleMolecular and cellular biochemistry2004
Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes.
Article in Molecular and cellular biochemistry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 37 citations in OpenAlex.
- ER stress improvement by aerobic training or enalapril differently ameliorates pathological cardiac remodeling in obese mice.Molecular and cellular biochemistry · 2024Article
- Obesity-induced skeletal muscle remodeling: A comparative analysis of exercise training and ACE-inhibitory drug in male mice.Physiological reports · 2024Article
- Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus.Diabetology & metabolic syndrome · 2023Article
- Application of Animal Models in Diabetic Cardiomyopathy.Diabetes & metabolism journal · 2021Review
- Role of Oxidative Stress in Metabolic and Subcellular Abnormalities in Diabetic Cardiomyopathy.International journal of molecular sciences · 2020Review
- Hyperglycemia-induced cardiac contractile dysfunction in the diabetic heart.Heart failure reviews · 2018Review
- Diabetic cardiomyopathy: where we are and where we are going.The Korean journal of internal medicine · 2017Review
- Contractile apparatus dysfunction early in the pathophysiology of diabetic cardiomyopathy.World journal of diabetes · 2015Review
- Mechanisms of subcellular remodeling in heart failure due to diabetes.Heart failure reviews · 2014Review
- Role of microangiopathy in diabetic cardiomyopathy.Heart failure reviews · 2014Review
- Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.Cardiovascular diabetology · 2013Article
- Diabetic cardiomyopathy: Pathophysiology, diagnostic evaluation and management.World journal of diabetes · 2013Review
- Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.Current cardiology reviews · 2010Article
- The complexities of diabetic cardiomyopathy: lessons from patients and animal models.Current diabetes reports · 2008Review
- Impaired cell communication in the diabetic heart. The role of the renin angiotensin system.Molecular and cellular biochemistry · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have shown that the renin-angiotensin system (RAS) is activated in diabetes and this may contribute to the subcellular remodelling and heart dysfunction in this disease. Therefore, we examined the effects of RAS blockade by enalapril, an angiotensin-converting enzyme inhibitor, and losartan, an angiotensin receptor AT1 antagonist, on cardiac function, myofibrillar and myosin ATPase activity as well as myosin heavy chain (MHC) isozyme expression in diabetic hearts. Diabetes was induced in rats by a single injection of streptozotocin (65 mg/kg; i.v.) and these animals were treated with and without enalapril (10 mg/kg/day; oral) or losartan (20 mg/kg/day; oral) for 8 weeks. Enalapril or losartan prevented the depressions in left ventricular rate of pressure development, rate of pressure decay and ventricular weight seen in diabetic animals. Both drugs also attenuated the decrease in myofibrillar Ca2+-ATPase, Mg2+-ATPase and myosin ATPase activity seen in diabetic rats. The diabetes-induced increase in beta-MHC content and gene expression as well as the decrease in alpha-MHC content and mRNA levels were also prevented by enalapril and losartan. These results suggest the occurrence of myofibrillar remodelling in diabetic cardiomyopathy and provide evidence that the beneficial effects of RAS blockade in diabetes may be associated with attenuation of myofibrillar remodelling in the heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.